Skip to content

Illumina

US · ILMN #539 by market cap Listed 1970
192.82 -7.84 -3.90%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions decreased by 4 in the most recent period (2026/Q4).
  • Total institutional ownership rose 0.2 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
108.58% +0.17pp
Institutions
1,329 -4
As of
2026/Q4 vs. prior period

Holder types

Mutual Fund93.44%
Hedge Fund5.14%
Public Company3.96%
Government Pension Fund2.38%
Private Company1.80%
Sovereign Wealth Fund0.62%
VC/PE Fund0.50%
Family Office/Trust0.29%
Insurance Company0.23%
Individual/Insider0.22%

Top holders as of 2026-09-30

BlackRock 10.48% · 15.85M sh
FMR 10.18% · 15.39M sh
Vanguard Capital Management, LLC 7.10% · 10.74M sh
Capital Research 6.65% · 10.05M sh
State Street Global Advisors 4.75% · 7.19M sh
Vanguard Portfolio Management, LLC 4.20% · 6.34M sh
WCM Investment Management 3.79% · 5.73M sh
Geode Capital Management, LLC 2.79% · 4.22M sh
PRIMECAP Management Company 2.31% · 3.49M sh
AQR Capital Management 1.98% · 2.99M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 15 buys · 35 sells

NameRoleStake
Jacob Thaysen Chief Executive Officer 0.03%
Keith Meister Director 0.51%
Steven Barnard Chief Technology Officer 0.03%
Kevin Pegels Chief of Global Operations 0.02%
Patricia Leckman Chief Human Resources Officer 0.01%
Scott Davies Corporate Secretary 0.01%
Philip Schiller Independent Director 0.01%
Robert Epstein Former Independent Director 0.01%
Frances Arnold Former Independent Director 0.01%
Susan Siegel Independent Director 0.01%
Jakob Wedel Chief Strategy & Corporate Development Officer 0.01%
Scott Ericksen Vice President 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-10 Corvex Management LP -- Open Market Disposition -280,091 $212.97–222.44
2026-11-09 Corvex Management LP -- Intent to Sell (Form 144) -375,000 $220.78
2026-11-09 Scott Ericksen Vice President Open Market Disposition -267 $217.76
2026-11-04 Kevin Pegels Chief of Global Operations Sale to Issuer -604 $208.00
2026-11-04 Scott Ericksen Vice President Sale to Issuer -150 $208.00
2026-11-04 Steven Barnard Chief Technology Officer Sale to Issuer -360 $208.00
2026-11-04 Patricia Leckman Chief Human Resources Officer Sale to Issuer -208 $208.00
2026-11-03 Corvex Management LP -- Open Market Disposition -281,433 $225.12–241.42
2026-11-02 Corvex Management LP -- Intent to Sell (Form 144) -369,501 $235.99
2026-10-04 Jacob Thaysen Chief Executive Officer Sale to Issuer -1,303 $293.69
2026-09-29 Keith Meister Independent Director Other Acquisition +107 $219.80
2026-09-29 Scott Ullem Independent Director Other Acquisition +113 $219.80
2026-09-07 Julie Coletti Chief Legal Officer Other Acquisition +18,763 --
2026-09-07 Julie Coletti Chief Legal Officer Other Derivative Acquisition +10,614 --
2026-09-04 Steven Barnard Chief Technology Officer Sale to Issuer -408 $211.06
2026-09-03 Keith Meister Director Open Market Disposition -263,560 $213.20–221.55
2026-09-03 Corvex Management LP -- Open Market Disposition -263,560 $213.20–221.55
2026-09-03 Corvex Management LP -- Intent to Sell (Form 144) -150,000 $213.25
2026-08-26 Keith Meister Director Open Market Disposition -375,941 $224.72–231.23
2026-08-26 Corvex Management LP -- Open Market Disposition -375,941 $224.72–231.23

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:00 · For reference only, not investment advice and not tailored to your situation.

Illumina discussion 0 comments

Add a comment